Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 3/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.45 |
| ▸ | CDK2 | P24941 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4023337 | 0.94 | PAK1 (0.56) | PAK1CCNE1CDK2LMNACNR1 | |
| SCHEMBL4018112 | 0.92 | DRD2 (0.44) | PAK1CCNE1CDK2DRD2HTR2A | |
| SCHEMBL4016296 | 0.84 | PAK1 (0.56) | PAK1CCNE1CDK2CNR1CNR2 | |
| SCHEMBL4024535 | 0.84 | CCNE1 (0.54) | CCNE1CDK2ALDH1A1 | |
| SCHEMBL4018132 | 0.82 | CNR1 (0.53) | PAK1CCNE1CDK2CNR1CNR2 | |
| SCHEMBL4016437 | 0.81 | CCNE1 (0.49) | PAK1CCNE1CDK2CNR1CNR2 | |
| SCHEMBL4022674 | 0.80 | CCNE1 (0.45) | PAK1CCNE1CDK2CNR1CNR2 | |
| SCHEMBL4020884 | 0.79 | PAK1 (0.63) | PAK1LMNACNR1CNR2MAP3K6 | |
| SCHEMBL4024310 | 0.79 | MEN1 (0.62) | PAK1CNR1CNR2DRD2HTR2A | |
| SCHEMBL4023546 | 0.78 | KMT2A (0.51) | PAK1CCNE1CDK2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066654-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | Bayer Schering Pharma AG (DE) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008028691-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |